MedTrace Logo

Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma

NCT06831773 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-02-18

No results posted yet for this study

Summary

The objective is to use the advantages of heavy ion physical dosimetry and biology to improve the tumor control rate and long-term survival rate of high-grade glioma, reduce the occurrence of brain tissue radiation damage caused by increasing prescription dose, and provide new treatment suggestions for glioma radiotherapy.

Conditions

  • Carbon Ion Radiotheray
  • High-grade Glioma
  • Heavy Ion Radiotherapy

Interventions

RADIATION

Carbon ion combined with photon radiotherapy

PTV1 was first treated with photon radiotherapy (started within 30 days after surgery), with a total dose of 50Gy, 25 times; After photon radiotherapy, PTV2 carbon ion radiotherapy was started, the total dose was 24.8Gy(RBE), 8 times. 3.1Gy(RBE)/fx; 1fx/ day, 5 days/week.

Sponsors & Collaborators

  • Gansu Wuwei Tumor Hospital

    lead OTHER

Principal Investigators

  • Xiaojun Li · Gansu Wuwei Tumor Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06831773 on ClinicalTrials.gov